[go: up one dir, main page]

UY31291A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO

Info

Publication number
UY31291A1
UY31291A1 UY31291A UY31291A UY31291A1 UY 31291 A1 UY31291 A1 UY 31291A1 UY 31291 A UY31291 A UY 31291A UY 31291 A UY31291 A UY 31291A UY 31291 A1 UY31291 A1 UY 31291A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
derivative
glucosido
pirazol
type
Prior art date
Application number
UY31291A
Other languages
Spanish (es)
Inventor
Michael Mark
Klaus Dugi
Leo Thomas
Frank Himmelsbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31291A1 publication Critical patent/UY31291A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a una composicion faramcéutica segun la reivindicacion 1, que comprende un derivado de pirazol-O-glucosido. combinado con un inhibidor de DPP IV que es adecuado en el tratamiento o la prevencion de una o más afecciones seleccionadas entre la diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, tolerancia anormal a la glucosa e hiperglucemia. Además, la presente invencion se refiere a métodos para prevenir o tratar trastornos metabolicos y afecciones relacionadas.The invention relates to a pharmaceutical composition according to claim 1, which comprises a pyrazole-O-glucoside derivative. combined with a DPP IV inhibitor that is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, abnormal glucose tolerance and hyperglycemia. In addition, the present invention relates to methods for preventing or treating metabolic disorders and related conditions.

UY31291A 2007-08-16 2008-08-14 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO UY31291A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114460 2007-08-16

Publications (1)

Publication Number Publication Date
UY31291A1 true UY31291A1 (en) 2009-03-31

Family

ID=39828484

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31291A UY31291A1 (en) 2007-08-16 2008-08-14 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO

Country Status (4)

Country Link
PE (1) PE20090597A1 (en)
TW (1) TW200911275A (en)
UY (1) UY31291A1 (en)
WO (1) WO2009022008A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
CN109503584A (en) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 Polymorphic
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
PE20090938A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
UY32177A (en) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
AR075204A1 (en) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
PT2395983T (en) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
KR20240090632A (en) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2368552A1 (en) 2010-03-25 2011-09-28 Boehringer Ingelheim Vetmedica GmbH 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
ES2953123T3 (en) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN103781788B (en) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 Quinazoline, its preparation and the purposes in pharmaceutical composition thereof being substituted
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
HUE064190T2 (en) 2013-04-04 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
EA034837B1 (en) 2013-12-17 2020-03-26 Бёрингер Ингельхайм Ветмедика Гмбх Treatment of metabolic disorders in feline animals
PL3485890T3 (en) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Sglt2 inhibitors for treatment of metabolic disorders in canine animals
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
EP3721882B1 (en) 2014-04-01 2024-08-28 Boehringer Ingelheim Vetmedica GmbH Treatment of pituitary pars intermedia dysfunction in equine animals
ES2991763T3 (en) 2014-09-25 2024-12-04 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for the prevention of metabolic disorders in equine animals
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin
CA3158368A1 (en) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors in the drying-off of non-human mammals
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN117715640A (en) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac disease in non-human mammals, excluding felines, especially canines
MX2024001185A (en) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
US20240390332A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003231517A1 (en) * 2002-04-26 2003-11-10 Ajinomoto Co., Inc. Preventive/remedy for diabetes
RS20120139A3 (en) * 2002-08-21 2015-02-27 Boehringer Ingelheim Pharma Gmbh&Co.Kg. 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
UY28103A1 (en) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
EP2119717B1 (en) * 2004-02-18 2018-01-17 Boehringer Ingelheim International GmbH 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors
DE102004044221A1 (en) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
GT200600218A (en) * 2005-06-10 2007-03-28 FORMULATION AND PROCESS OF DIRECT COMPRESSION
UY29694A1 (en) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO
PE20080251A1 (en) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
CL2008000133A1 (en) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND

Also Published As

Publication number Publication date
WO2009022008A1 (en) 2009-02-19
PE20090597A1 (en) 2009-06-06
TW200911275A (en) 2009-03-16

Similar Documents

Publication Publication Date Title
UY31291A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
UY31290A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-O-GLUCOSIDO
UY31296A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A SUBSTITUTED BENZENE DERIVATIVE WITH GLUCOPIRANOSIL
UY31295A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY AN SGLT2 INHIBITOR
UY32441A (en) PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND ITS USES
CO6781465A2 (en) Pharmaceutical composition, treatment methods and uses thereof
UY33700A (en) ? PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS ?.
CO6410306A2 (en) SGLT2 INHIBITOR TO TREAT MELLITUS DIABETES OF TYPE 1, MELLITUS DIABETES OF TYPE 2, ALTERATION OF TOLERANCE TO GLUCOSE AND HYPERGLUCEMIA
ECSP099037A (en) METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS
AR064969A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A PIRAZOL DERIVATIVE -OR- GLUCOSIDE
EA201101187A1 (en) ANTI-DIABETIC MEDICINES CONTAINING DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONAL IN COMBINATION WITH OTHER ANTI-DIABETIC MEANS
CO6341636A2 (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
DOP2009000283A (en) SIRTUINA MODULATING COMPOUNDS
CO6410287A2 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, TREATMENT METHODS AND USES OF THE SAME
CO6270312A2 (en) MODULATORS OF GPR40 BIFENILO-SUBSTITUTES
NI200800328A (en) METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS.
ECSP10010106A (en) TRANS-CLOMPHENE FOR METABOLIC SYNDROME
AR090999A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
CO6270306A2 (en) INHIBITOR COMPOSITE OF GOSPHORILASE GLICOGEN AND PHARMACEUTICAL COMPOSITION OF THE SAME
PA8787001A1 (en) "DERIVATIVES OF MACROLACTONA"
TN2013000187A1 (en) Pharmaceutical composition, methods for treating and uses thereof
ECSP045079A (en) N-REPLACED PIRROLIDIN DERIVATIVES AS INHIBITORS OF DIPEPTIDIL PEPTIDASA IV
CL2010000775A1 (en) Glucopyranosyl substituted 3-benzyl benzene derivative compounds; pharmaceutical composition; pharmaceutical combination comprising said compounds; and its use for the treatment or prevention of metabolic diseases such as diabetes, among others (divisional application 566-05).

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180108